2366 related articles for article (PubMed ID: 25468140)
1. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
2. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
3. Recent developments and future perspectives of personalized oncology.
Grüllich C; von Kalle C
Onkologie; 2012; 35 Suppl 1():4-7. PubMed ID: 22286581
[TBL] [Abstract][Full Text] [Related]
4. Biomarker update for breast, colorectal and non-small cell lung cancer.
Ross JS
Drug News Perspect; 2010; 23(1):82-8. PubMed ID: 20155222
[TBL] [Abstract][Full Text] [Related]
5. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.
Normanno N; Rachiglio AM; Roma C; Fenizia F; Esposito C; Pasquale R; La Porta ML; Iannaccone A; Micheli F; Santangelo M; Bergantino F; Costantini S; De Luca A
J Cell Biochem; 2013 Mar; 114(3):514-24. PubMed ID: 22991232
[TBL] [Abstract][Full Text] [Related]
6. Use of molecular markers for predicting therapy response in cancer patients.
Duffy MJ; O'Donovan N; Crown J
Cancer Treat Rev; 2011 Apr; 37(2):151-9. PubMed ID: 20685042
[TBL] [Abstract][Full Text] [Related]
7. The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.
Rossi G; Graziano P; Leone A; Migaldi M; Califano R
Semin Diagn Pathol; 2013 Nov; 30(4):298-312. PubMed ID: 24342286
[TBL] [Abstract][Full Text] [Related]
8. Molecular testing in breast cancer.
Paoletti C; Hayes DF
Annu Rev Med; 2014; 65():95-110. PubMed ID: 24422569
[TBL] [Abstract][Full Text] [Related]
9. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
[TBL] [Abstract][Full Text] [Related]
10. Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community?
Arnedos M; Soria JC; Andre F; Tursz T
Cancer Treat Rev; 2014 Dec; 40(10):1192-8. PubMed ID: 25441102
[TBL] [Abstract][Full Text] [Related]
11. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for lung cancer: present and future.
Aggarwal C
Ann Palliat Med; 2014 Jul; 3(3):229-35. PubMed ID: 25841697
[TBL] [Abstract][Full Text] [Related]
13. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
14. Pathways to personalized medicine for breast and prostate cancers: emerging diagnostic methods and prognostic biomarkers.
Watson AP; Egland KA
S D Med; 2010 Jul; 63(7):247-53. PubMed ID: 20666024
[TBL] [Abstract][Full Text] [Related]
15. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
[TBL] [Abstract][Full Text] [Related]
16. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center.
Wiesweg M; Ting S; Reis H; Worm K; Kasper S; Tewes M; Welt A; Richly H; Meiler J; Bauer S; Hense J; Gauler TC; Köhler J; Eberhardt WE; Darwiche K; Freitag L; Stamatis G; Breitenbücher F; Wohlschlaeger J; Theegarten D; Derks C; Cortes-Incio D; Linden G; Skottky S; Lütkes P; Dechêne A; Paul A; Markus P; Schmid KW; Schuler M
Eur J Cancer; 2013 Oct; 49(15):3076-82. PubMed ID: 23876834
[TBL] [Abstract][Full Text] [Related]
18. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.
Dowsett M; Dunbier AK
Clin Cancer Res; 2008 Dec; 14(24):8019-26. PubMed ID: 19088018
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
20. The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer.
Brennan M; Lim B
Adv Exp Med Biol; 2015; 867():327-37. PubMed ID: 26530375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
